ABEO
NASDAQ HealthcareAbeona Therapeutics Inc. - Common Stock
Biotechnology
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
๐ Market Data
| Price | $5.43 |
|---|---|
| Volume | 681,081 |
| Market Cap | 308.87M |
| Beta | 1.210 |
| RSI (14-Day) | 63.9 |
| 200-Day MA | $5.42 |
| 50-Day MA | $4.99 |
| 52-Week High | $7.54 |
| 52-Week Low | $4.00 |
| P/E Ratio | 5.38 |
| Forward P/E | 22.62 |
| Price / Book | 1.88 |
๐ฏ Investment Strategy Scores
ABEO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (70/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ABEO in your text
Paste any article, transcript, or post โ the tool will extract ABEO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.